[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-410427-105":59,"doc-detail-410427-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","omadacycline-pharmacokinetics-characteristics-contributing-factors-and-clinical-significance-review","Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance - Review","","Omadacycline is a novel tetracycline with broad antibacterial activity, and optimizing its therapeutic value requires a clear understanding of the factors that govern its metabolic and pharmacokinetic behavior. The review explains that its metabolism does not depend on UDP-glucosyltransferase or cytochrome P450 enzymes, supporting advantages in drug-interaction risk, bioavailability, and metabolic stability. It synthesizes evidence on intrinsic properties, inter-individual variability, dietary influences, and potential drug interactions, aiming to improve dosing customization, efficacy, and safety across populations and disease states.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/omadacycline-pharmacokinetics-characteristics-contributing-factors-and-clinical-significance-review/410427/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/omadacycline-pharmacokinetics-characteristics-contributing-factors-and-clinical-significance-review/410427.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main focus of this review on omadacycline?","Question",{"text":113,"@type":114},"The review analyzes omadacycline pharmacokinetics, including key determinants of its metabolic processes, differences across populations and disease conditions, and implications for clinical use.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which enzymes are reported as not being required for omadacycline metabolism?",{"text":118,"@type":114},"Omadacycline metabolism is reported not to rely on UDP-glucosyltransferase or cytochrome P450 enzymes.",{"name":120,"@type":111,"acceptedAnswer":121},"How does omadacycline compare with other antibiotics in clinical effectiveness for specific infections?",{"text":122,"@type":114},"In CABP, omadacycline is reported as not inferior to moxifloxacin overall, while clinical success against H. influenzae is reported lower than moxifloxacin. For ABSSSI, omadacycline is reported as as effective as linezolid in the discussed studies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},410427,1790792654,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Drugs in R&D (2025) 25:289–307  \n[https://doi.org/10.1007/s40268-025-00531-8](https://doi.org/10.1007/s40268-025-00531-8)  \nOmadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance  \nHuan Sun1 · Xiaoli Hou1 · Qiuzhen Zhu1 · Juan Liu1 · Qiaoli Zhai1 · Kourong Shi1  \nReceived: 22 June 2025 / Accepted: 12 November 2025 / Published online: 11 December 2025 © The Author(s) 2025  \nAbstract  \nOmadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential negative effects. It was found that the metabolism of omadacycline does not rely on UDP-glucosyltransferase or cytochrome P450 enzymes, which gives it a clear advantage in terms of drug interactions, bioavailability, and metabolic stability. The review offers a thorough analysis of the many elements influencing the pharmacokinetics of omadacycline, including its intrinsic properties, individual differences, dietary influences, and possible drug interactions. To achieve maximum efficacy and safety in clinical practice, a thorough understanding of the pharmacokinetic properties of omadacycline is essential, which helps to better customize dosing regimens and maximize therapeutic outcomes.  \nKey Points  \nThis review covers the latest research on the pharmacology and pharmacokinetics of omadacycline in the past 5 years and provides an in-depth analysis of the differences between omadacycline and other tetracyclines in terms of the antibacterial spectrum and pharmacokinetics. It is of great significance to optimize the clinical drug regimen, improve drug safety, and avoid drug interactions.  \nIn this review, the pharmacokinetic characteristics of omadacycline in different populations and disease conditions are analyzed in detail, and the relationship between the mechanism of action and the clinical application effect is analyzed.  \n* Kourong Shi[shikourong@163.com](shikourong@163.com)  \n1 Department of Pharmacy, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, No.  \n358 Datong Road, Shanghai 200137, China  \n1 Introduction  \nA major public health concern is the growing threat of extensive and multi-drug-resistant bacteria brought on by bacterial evolution and antibiotic abuse. According to the World Health Organization, carbapenem-resistant Gramnegative bacteria are among the most troublesome pathogens in the world and present a serious clinical challenge. Tetracyclines, a class of broad-spectrum antibiotics, are essential in the fight against these resistant bacteria by attaching to the 30S subunit of the bacterial ribosome and preventing bacterial protein synthesis [1] . The journey of tetracycline as an effective antibiotic against a variety of pathogens, such as Mycoplasma, Chlamydia, and Legionella, began in 1948 with the discovery of chlortetracycline. Since then, a number of additional tetracyclineshave emerged by isolation or derivatization, including metacycline, doxycycline, and minocycline [2] . Tetracyclines have been widely used over the years to treat a variety of bacterial infections, including leptospirosis, chlamydia infection, mycoplasma infection, rickettsiosis, acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP) [3 , 4] . Glycylcyclines, a subclass of tetracyclines, have shown promise in treating infections brought on by carbapenemresistant Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae. Multi-drug-resistant bacterial infections can be effectively treated with tetracyclines such  \nas tigecycline, minocycline, omadacycline, and eravacycline. Furthermore, tetracyclines have also shown promise in the treatment of tumors and periodontitis, broadening their range of therapeutic uses beyond conventional infectious diseases [5–7] .  \nOmadacycline (Nuzyra","cbCaik520MEePLC5","https://ap.wps.com/l/cbCaik520MEePLC5","pdf",2437174,"English","# Abstract\n# Key Points\n# Introduction\n## Tetracyclines and resistant bacteria\n## Omadacycline background and clinical evidence","[{\"question\":\"What is the main focus of this review on omadacycline?\",\"answer\":\"The review analyzes omadacycline pharmacokinetics, including key determinants of its metabolic processes, differences across populations and disease conditions, and implications for clinical use.\"},{\"question\":\"Which enzymes are reported as not being required for omadacycline metabolism?\",\"answer\":\"Omadacycline metabolism is reported not to rely on UDP-glucosyltransferase or cytochrome P450 enzymes.\"},{\"question\":\"How does omadacycline compare with other antibiotics in clinical effectiveness for specific infections?\",\"answer\":\"In CABP, omadacycline is reported as not inferior to moxifloxacin overall, while clinical success against H. influenzae is reported lower than moxifloxacin. For ABSSSI, omadacycline is reported as as effective as linezolid in the discussed studies.\"}]","Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance - Review | PDF",1790585258,48]